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Abstract
Background: In HIV-infected pregnant women, viral suppression prevents mother-to-child HIV transmission. Directly
observed highly-active antiretroviral therapy (HAART) enhances virological suppression, and could prevent transmission.
Our objective was to project the effectiveness and cost-effectiveness of directly observed administration of antiretroviral
drugs in pregnancy.
Methods and Findings: A mathematical model was created to simulate cohorts of one million asymptomatic HIV-infected
pregnant women on HAART, with women randomly assigned self-administered or directly observed antiretroviral therapy
(DOT), or no HAART, in a series of Monte Carlo simulations. Our primary outcome was the quality-adjusted life expectancy in
years (QALY) of infants born to HIV-infected women, with the rates of Caesarean section and HIV-transmission after DOT use
as intermediate outcomes. Both self-administered HAART and DOT were associated with decreased costs and increased life-
expectancy relative to no HAART. The use of DOT was associated with a relative risk of HIV transmission of 0.39 relative to
conventional HAART; was highly cost-effective in the cohort as a whole (cost-utility ratio $14,233 per QALY); and was cost-
saving in women whose viral loads on self-administered HAART would have exceeded 1000 copies/ml. Results were stable
in wide-ranging sensitivity analyses, with directly observed therapy cost-saving or highly cost-effective in almost all cases.
Conclusions: Based on the best available data, programs that optimize adherence to HAART through direct observation in
pregnancy have the potential to diminish mother-to-child HIV transmission in a highly cost-effective manner. Targeted use
of DOT in pregnant women with high viral loads, who could otherwise receive self-administered HAART would be a cost-
saving intervention. These projections should be tested with randomized clinical trials.
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Introduction
Mother-to-child transmission is the most common cause of
pediatric human immunodeficiency virus (HIV) infection in North
America. United States surveillance data identified 139 newly
recognized HIV infections in children of mothers with HIV
infection in the U.S. in 2007; over 9,500 children with likely
vertical acquisition of HIV infection have developed AIDS since
the HIV epidemic began [1]. Maternal viral load in the third
trimester of pregnancy is a strong predictor of risk of HIV
transmission to the newborn, and its reduction through the use of
highly-active antiretroviral therapy (HAART) appears to markedly
reduce the risk of peripartum HIV transmission [2,3,4,5].
Recognition of the large potential impact of maternal HIV
replication on transmission has resulted in revision of U.S. and
European guidelines on antiretroviral use in pregnancy [6,7,8,9].
These guidelines have long advocated the use of HAART in
pregnancy for prevention of transmission, and HAART is now the
standard of care for all pregnant HIV-infected women [6].
Adherence to a HAART regimen predicts suppression of viral
replication and reduces the potential for emergence of resistant
viral strains [10,11,12,13]. Drug adherence is suboptimal in
up to one-third of HIV-infected women of childbearing age
[14,15,16,17], notwithstanding increases in HAART compliance
during pregnancy; mother-to-child transmission still occurs in
1–3% of infants born to HIV-infected women receiving antiret-
roviral treatment [17]. As low adherence to anti-retroviral
therapies is significantly associated with mortality and increased
risk of mother-to-child transmission [16,17], it is important to
establish other means of improving adherence in this high-risk
group in order to improve clinical outcomes in both mothers and
their infants.
Directly observed therapy (DOT) is used in the treatment of
tuberculosis to enhance the likelihood of treatment success and
minimize the emergence of drug-resistant microbes, and has been
proposed as a means of improving adherence to HAART [18,19].
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medications must be given daily, making the routine use of directly
observed HAART problematic. Recent randomized trials have
demonstrated significant reductions in viral load in individuals
receiving DOT for HIV infection, although this response may not
be durable after discontinuation of DOT [20,21,22]. Nonetheless,
in prisons and community-based settings, the use of DOT for HIV
infection has been associated with a reduction in viral burden of 1
to 2 log, even in antiretroviral-experienced individuals
[19,20,23,24,25,26].
The third trimester of pregnancy may present a unique
opportunity for use of directly observed HAART in that the time
horizon is limited. In addition to virologic suppression for the
prevention of mother-to-child transmission of HIV, directly
observed HAART could preserve the future potency of antiret-
roviral drug classes by limiting emergence of resistance in
pregnant women taking these medications solely to prevent
transmission. Furthermore, DOT could potentially be an
economically attractive intervention, since, if successful, down-
stream medical costs associated with pediatric HIV infection will
be prevented.
The small number of perinatally infected infants makes it
challenging to study the impact of DOT-HAART for prevention
of perinatal HIV transmission in the context of a prospective,
randomized trial; in the absence of such a trial, simulations that
aggregate the best available data may be a useful tool to optimize
policy under uncertainty. Our objective was to use a simulation
model to project the costs and clinical benefits that would be
expected to result from the use of DOT in women receiving
HAART in the third trimester of pregnancy.
Methods
The Model
We constructed a probabilistic model of HIV infection in
pregnancy to project the impact of directly observed HAART on
vertical HIV transmission by HIV-infected women receiving
treatment by the 3
rd trimester of pregnancy (before 28 weeks
gestation) according to current U.S. Department of Health and
Human Services guidelines [6] (Figure 1), with some proportion
of these women having started HAART prior to pregnancy for
their own health, and some proportion starting within the first two
Figure 1. Simplified Depiction of Model Tree Structure. Pregnant women with HIV infection enter the third trimester of pregnancy already on
highly-active antiretroviral therapy, with or without direct observation. Round ‘‘nodes’’ represent chance events, while squares represent clinical
decisions. Women either experience preterm or term delivery, with a viral load (VL, in copies/ml) that is a function of baseline viral load, effectiveness
of antiretroviral drugs, and the availability of directly observed therapy. For both detectable and undetectable viral load responses, a proportiono f
women receive emergency Caesarean sections. Delivery may otherwise be by elective Caesarean section, or by vaginal delivery. Vaginal delivery is an
option only in women with low viral loads on antiretroviral therapy. Health outcomes in the infant are predicted by prematurity (not shown) and the
occurrence of mother-to-child transmission.
doi:10.1371/journal.pone.0010154.g001
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child HIV transmission. Clinical and cost outcomes were projected
for a hypothetical cohort of women with asymptomatic HIV
infection and CD4-positive lymphocyte counts .200 copies/ml.
Women receiving HAART enter the model in the 3
rd trimester
of pregnancy. We assumed that all transmission occurs in the third
trimester of pregnancy or in the peripartum period, and that the
probability of transmission is conditional on the maternal viral
load at the time of parturition. We incorporated the risk of
preterm birth and the subsequent elevated risk of neonatal death,
and the relative risks associated with emergency and elective
Caesarean section and vaginal delivery. We assumed all infants
would be formula-fed, making acquisition of HIV through breast
feeding unlikely [27,28].
Strategies
We used our model to project downstream costs and
consequences associated with self-administered HAART and
directly observed HAART. For both strategies we assumed
patients would receive otherwise standard obstetrical manage-
ment. HAART was assumed to consist of a combination of two
nucleoside reverse transcriptase inhibitors (excluding the combi-
nation of didanosine and stavudine) and one or two viral protease
inhibitors, with the regimen dosed one or two times daily [6]. We
assumed that non-nucleoside reverse transcription inhibitors
would not be routinely used for longitudinal therapy in the third
trimester [6]. Although current guidelines recommend that all
women receive combination antiretroviral therapy in pregnancy,
for their own health and/or to prevent vertical transmission [6],
we added a hypothetical ‘‘no HAART’’ arm by removing the
virological benefits and potential toxicity of HAART, in order to
evaluate the cost-effectiveness of both antiretroviral strategies
relative to no treatment.
DOT was assumed to consist of daily home visits by a trained
public health worker, with observation of the first dose of
antiretroviral drugs. If a second daily dose was required, it would
be self-administered, as described elsewhere [19]. Standard
obstetrical management was considered to consist of monthly
visits in the third trimester. Elective Caesarean section delivery was
assumed to occur before the rupture of membranes and onset
of labour, and was associated with a reduced risk of HIV
transmission. Emergency Caesarean delivery was operative
delivery after the rupture of membranes and/or onset of labor,
and was not associated with a reduced risk of transmission. We
assumed that elective Caesarean section was performed in women
with viral loads .1,000 copies/ml at term not requiring
emergency Caesarean section [6]. Where viral load was ,1,000
copies/ml at term and emergency Caesarean section was not
required, women could receive either elective Caesarean section or
a vaginal delivery. We explored the costs and benefits associated
with targeted use of DOT among certain subgroups of women.
Parameterization and Calibration
Probabilities and ranges used in the model were derived from
published medical literature obtained through keyword searches
on MEDLINE, and through consultation with expert clinicians
involved in treatment of pregnant women with HIV infection
(Table 1). Individual women’s baseline viral load ‘‘set points’’ (i.e.,
the approximate viral load that would be expected in that
individual in the absence of antiretroviral therapy [29]) were
drawn at random from a log-normal distribution. The baseline
viral load distribution was constructed using viral loads observed in
a cohort of 180 antiretroviral-naı ¨ve men [30], and reduced by 0.25
log to account for the possibility that viral set point is lower in
women [31]. The impact of self-administered HAART was
simulated by reducing the baseline viral load using data on the
effectiveness of HAART from the Women’s Interagency HIV
Study (WIHS) [32]. In women assigned to DOT, viral load was
reduced again by a log quantity drawn randomly from a triangular
distribution, to simulate the increase in adherence reported in
association with directly observed HAART [19,23,24,25]. In the
base case, we assumed that toxicity secondary to HAART in the
developing infant would not be enhanced by directly observed
HAART.
To ensure model validity, we calibrated parameters to so that
outcomes would approximate those observed in a 2005 European
Collaborative Study that showed the effectiveness of HAART in
preventing mother-to-child HIV transmission in a cohort study of
over 4000 mother-child pairs [33]. We calibrated values for the
proportion of women with a viral load ,200 copies/ml and the
probability of vertical transmission at all viral loads, and we
empirically inflated the rates of Caesarean sections (both
emergency and elective) and premature births to more closely
match the European study’s proportions.
Our primary outcome of interest was the quality-adjusted life
expectancy (QALY) of infants born to women with HIV infection.
Quality-adjusted survival estimates in HIV-infected children
incorporated patient-derived, preference-based utility measures
[34], in combination with survival estimates reported for pediatric
populations and (because most infants will survive to adulthood)
adult populations since the advent of HAART [34,35,36,37].
Intermediate outcomes of interest included the number of
Caesarean sections performed, and the number of HIV infections
in infants under each strategy.
We estimated costs from a societal perspective, including future
healthcare costs associated with new HIV infections in infants
[38,39,40,41,42,43,44]. The cost of delivery and direct observa-
tion of antiretroviral therapy was assumed to be equivalent to that
described for tuberculosis-related directly observed therapy
[45,46]. All costs were converted to 2008 U.S. dollars using the
Consumer Price Index for Medical Care Services [47], and future
costs were discounted using a 3% annual rate in the base case [48].
A health care intervention is considered to be ‘‘cost-saving’’
when it costs less but provides incremental benefit relative to a
competing intervention; ‘‘highly cost-effective’’ when it costs less
than the GDP per capita; and ‘‘cost-effective’’ when it is between
one and three times a country’s GDP per capita [49]. A cost-
saving intervention is always preferred to competing programs or
strategies [49,50].
Simulations
We generated estimates of costs and consequences of competing
strategies through a series of Monte Carlo simulations. Such
simulations utilize a random-number generator to create unique,
simulated individual patients, and move them through a series of
chance events over time [51,52]. A running tally of outcomes,
costs, and events is recorded, with the creation of simulated
cohorts that can be compared to one another. Unless otherwise
stated, results presented here are each based on five thousand
simulations of 200-person clinical trials, with 100 women
randomized to directly observed HAART and 100 women
randomized to self-administered HAART in each trial.
Sensitivity Analyses
We evaluated our model assumptions and data inputs by
performing univariate and bivariate sensitivity analyses. A
plausible range was established for each parameter using the
highest and lowest values in the published literature or confidence
DOT for HIV in Pregnancy
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Variable Value (Range) Reference
Baseline log10 viral load (6SD) 3.75 (60.8) [30,31]
Probability of virologic response to HAART without DOT *
Complete response 0.35 (0–1) [32] and calibration
Partial response 0.42 (0–0.65) [32] and calibration
Non-response 0.23 (0–0.5) [32] and calibration
Log10 reduction in viral load with DOT 0.8 (0.1–1.5) [20,21,22]
Probability of non-elective Caesarean section { 0.16 [59] and calibration
Probability of Caesarean section (elective and non-elective) 0.60 [60] and calibration
Probability of premature delivery {{ 0.2 (0.06–0.27) [58,61]
Probability of antiretroviral toxicity 1 0 (0.005–0.05) [6,62,63,64,65]
Probability of vertical transmission of HIV I
Maternal viral load .10,000 copies/ml 0.21 (0.13–0.28) [2,5] and calibration
Maternal viral load 1,000–10,000 copies/ml 0.13 (0.06–0.21) [2,5] and calibration
Maternal viral load ,1,000 copies/ml 0.0015 (0–0.002) [2,5] and calibration
Relative risk of transmission with elective Caesarean section 0.4 (0.2–0.6) [59,66]
Relative risk of drug toxicity with DOT 1 (1–5) [67] and best estimate
Discounted QALY, infant "
HIV uninfected 28 (28–29)
HIV infected ** 9 (8–15)
Reduction in QALE (%)
Prematurity {{ 20 (15–30) [68,69,70]
Drug toxicity 0 (10–40) Best estimate
Costs
HAART x one trimester $4890 ($3750–$5640) [6,71,72]
Peripartum zidovudine {{ $550 ($410–$740) [6,72]
Directly observed therapy $2630 ($2630–$21,000) [45,46]
Vaginal delivery $3610 ($2370–$10,380) [38,73]
Caesarean section $6570 ($5260–$15,110) [38,73]
Lifetime costs, prematurity "1 1 $278,600 ($214,200–$407,400) [68,74,75,76]
Lifetime healthcare costs, drug toxicity $0( $65,700–$262,800) Best estimate
Lifetime healthcare costs, pediatric HIV infection " $289,000 ($140,600–$660,930) [38,40,41,42,43,44,77]
Discount rate (%) 3 (0–10) [48]
NOTE: HAART, highly-active antiretroviral therapy; DOT, directly observed therapy; QALE, quality-adjusted life expectancy.
* Complete response considered to be a sustained reduction in viral load of 2.0 log10 copies/ml; partial response considered to be a sustained reduction of 0.75 log10
copies/ml; non-response associated with a reduction of 0.25 log10 copies/ml [32].
{ Non-elective Caesarean at term and Caesarean section with premature delivery were not associated with reduced risk of mother-to-child HIV transmission [59].
{ Base-case probability of prematurity approximates that seen in a cohort of HIV-infected New York Medicaid recipients; upper bound based on rates of premature
delivery seen in a subgroup of women receiving methadone maintenance therapy [58].
1 In base case, risk of antiretroviral toxicity in infants was assumed to be negligible, consistent with available data [6,62,65]. Risk of severe toxicity used in sensitivity
analysis based on upper bound confidence limit for mitochondrial toxicity in a French cohort study [63,64]. Risk of moderate toxicity based on best estimate of plausible
upper bound.
I Base-case estimates and ranges for viral loads greater than 1000 copies/ml derived based on outcomes among individuals receiving peripartum zidovudine in a
prospective multi-centre study of HIV in pregnancy [5].
" QALY and lifetime cost estimates presented in table based on the use of a 3% discount rate. Base-case quality-adjustment for HIV-uninfected individuals 45 years of
age and older performed using community-derived utility estimates, as described in [78], while upper bound estimates are not quality-adjusted.
** Quality-adjusted survival in HIV-infected infants was estimated based on the assumption that 2/3 of person-time with HIV infection would be symptom-free, while 1/3
of person-time with HIV would include HIV-attributable symptoms. Acquired immune deficiency syndrome was assumed to be present in the last two years of life.
Death due to HIV in infected children has declined markedly in both the U.S. and Europe with the advent of HAART, making estimation of survival in HIV-infected
children difficult due to small numbers of events [35,37]. Survival in HIV-infected children was assumed to approximate that seen in the youngest adults treated with
HAART [36]. Lower bound survival estimates for HIV were generated using community-derived utility weights for life with HIV infection [34], while upper bound
estimates were generated using more favorable survival estimates, and without quality-adjustment [79].
{{ Based on in-hospital mortality in 15% of premature infants (including third-trimester still-births), with a risk of moderate to severe cognitive impairment in 10–30%
[68,70,76]. Reduction in quality-adjusted survival estimated based on health utility weight of 0.67 predicted for an individual with moderate cognitive and sensory
impairment and impaired self-care ability using the Health Utilities Index Mark II [69].
{{ Basedon intravenous zidovudine during 12 hourlabor, andaverage doseof 1 ml zidovudine syrup(10 mg/ml) administered to neonate qidfor 6 weekspostpartum [6].
11 Estimated based on weighted average healthcare costs associated with prematurity in infants born from 28 to 36 weeks of gestation in the state of California [75],
with future costs occurring due to developmental delay in 15–30% of surviving infants [68,74,76,80].
doi:10.1371/journal.pone.0010154.t001
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to those used in the base case analysis. When only one data point
was available for a given parameter, we established plausible
ranges through the use of expert opinion.
Results
Model Calibration
Our final model was well calibrated to outcomes observed in a
large European cohort study of pregnant women with HIV
infection; we chose to calibrate our model to this study because it
was the largest available study conducted in a context where
HAART was widely available [33]. Final model parameter sets
applied to the self-administered HAART strategy reproduced risks
of mother-to-child HIV transmission, reduction in viral load in
mothers receiving standard HAART, and risk of both emergency
and elective Caesarean section reported in this study (Figure 2).
The ‘‘no HAART’’ strategy in the model reproduced rates of
vertical transmission consistent with those seen in trials of zido-
vudine and Cesarean section for prevention of HIV transmission
[53,54].
Effectiveness and Cost-Effectiveness of Directly Observed
HAART
The outcomes of five thousand simulated randomized con-
trolled trials of directly observed HAART, compared to self-
administered HAART, are presented in Figure 3. While we did
include a ‘‘no HAART’’ strategy in our model, this strategy
resulted in increased net costs and reduced quality-adjusted life
expectancy relative to the self-administered HAART and directly
observed HAART strategies in the cohort as a whole, and thus
would never be preferred.
A reduction in the probability of mother-to-child HIV
transmission was seen with directly observed HAART in most
trials, with a projected average relative risk of HIV infection of
0.39 among infants born to women receiving DOT versus those
receiving self-administered HAART, and a relative risk of 0.09 as
compared to women receiving no HAART (Table 2). The
reduction in viral load among women receiving directly observed
HAART also decreased the requirement for elective Caesarean
section among women giving birth at term. There was a resultant
average increase in the projected quality-adjusted survival of 11
quality adjusted life-days among infants born to women receiving
directly observed antiretrovirals.
On average, direct observation of HAART in the third
trimester was projected to be a highly cost-effective intervention,
with gains in quality-adjusted survival described above accompa-
nied by net societal costs of $14,233. When trials were stratified
according to participants’ baseline viral loads, directly observed
HAART was projected to be a cost-saving intervention in cohorts
with viral loads above 1000 copies/ml. We projected savings of
$54,278 per QALY in individuals with viral loads between 1,000
and 10,000 copies/ml, and savings of $26,240 per QALY in
individuals with viral loads .10,000 copies/ml (Table 3).
Sensitivity Analyses
We performed wide-ranging sensitivity analyses by varying
parameter values and using alternate model assumptions
(Table 4). The projected attractiveness of directly observed
therapy was insensitive to plausible changes in most model
variables, including the probabilities of vertical HIV transmission,
prematurity, and emergency and elective Caesarean section;
obstetrical costs; and future costs associated with HIV infection
and prematurity. Projections were somewhat sensitive to the
Figure 2. Model Calibrations. The model was calibrated to a 2005 European Collaborative Study that examined the effect of HAART on prevention
of mother-to-child transmission in over 4000 mother-child pairs [33]. We calibrated the output of our model’s self-administered therapy branch to the
European study’s results for proportion of women receiving an emergency C-section; proportion of women receiving an elective Cesarean section;
proportion of women with an undetectable viral load (less than 200 copies/ml); and percent of HIV transmission to the infant.
doi:10.1371/journal.pone.0010154.g002
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effectiveness without directly observed therapy), and the effective-
ness of directly observed therapy. Projections were highly sensitive
to the enhancement of toxicity of HAART as a result of greater
drug exposure with directly observed therapy.
In our base case analysis, we assumed that the costs of direct
observation of HAART would be due to personnel time required
to deliver and observe administration of medications. However,
creation of a novel program could be associated with other fixed
and capital costs (office space and supplies, acquisition of vehicles,
Figure 3. Projected Cost-Effectiveness of Directly Observed Highly-Active Antiretroviral Therapy in Pregnancy. The estimated cost-
effectiveness of directly observed highly-active antiretroviral therapy (HAART) as compared to self-administered HAART. Each grey circle represents
one of 5000 simulated trials comparing the two strategies, with 200 women in each trial. The incremental cost of directly observed therapy is on the
Y-axis, while the incremental change in quality-adjusted life expectancy among infants is on the X-axis. Under base-case assumptions, directly
observed therapy reduced costs and increased quality-adjusted life expectancy in most trials.
doi:10.1371/journal.pone.0010154.g003
Table 2. Projected Average Cost and Effectiveness of Directly Observed HAART in 5000 Simulated Randomized Trials.
Strategy
Average
Cost
% Requiring
Caesarean
Section
% Mother-to-
Child HIV
Transmission
Infant’s Quality-
Adjusted Life
Expectancy
Incremental Cost-
Effectiveness
Ratio ($/QALY)
All Trials
Self-administered HAART $73,043 70.5 1.22 29.71 ——
HAART with Directly Observed
Therapy
$73,470 67.8 0.48 29.74 Highly cost-effective * ($14,233)
No HAART $77,012 84.9 5.44 29.55 Dominated *
NOTE: HAART, highly-active antiretroviral therapy; QALY, quality-adjusted life years.
* A health care intervention is ‘‘dominated’’ if it costs more, but provides less health benefit, than a competing intervention. A dominated health intervention is never
preferred [50]. A health care intervention is considered to be ‘‘cost-saving’’ when it costs less, but provides more health than, a competing intervention; ‘‘highly cost-
effective’’ when it costs less than the GDP per capita; and ‘‘cost-effective’’ when it is between one and three times a country’s GDP per capita. A cost-saving intervention
is always preferred [49,50].
doi:10.1371/journal.pone.0010154.t002
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effectiveness and cost of directly observed HAART in pregnancy
are presented in Figure 4. When we biased our analysis against
directly observed therapy by increasing the cost of drug delivery
four-fold, and by reducing the effectiveness of direct observation to
a 0.5 log change in viral load, the cost-effectiveness ratio associated
with this strategy was $313,000 per QALY, a ratio that exceeds a
commonly cited threshold for cost-effectiveness [49]. However,
this is an extremely unfavourable assumption [50,55]. Most other
combinations of DOT effectiveness and cost were cost-effective or
cost-saving, relative to self-administered HAART.
We postulated that concern for a developing infant might result
in enhanced adherence to self-administered HAART by pregnant
women with HIV infection. We simulated such an effect by
increasing the likelihood that pregnant women taking HAART
would have a full (i.e., 2 log10) decrease in viral load with self-
administered HAART (Figure 5). As baseline antiretroviral
effectiveness of self-administered HAART improved, directly
observed administration became less economically attractive at
all tested willingness-to-pay (WTP) thresholds. The incremental
cost-effectiveness ratio of DOT was cost-effective (under $50,000,
a commonly cited cost-effectiveness threshold) as long as the
proportion of women responding fully to self-administered
HAART was under 0.6.
Discussion
Mother-to-child HIV transmission remains an important but
potentially preventable consequence of HIV infection in repro-
ductive-age women. Although improvements in obstetrical
management of HIV-infected women have greatly reduced the
incidence of perinatal HIV infection, women now comprise 25%
of those with newly diagnosed HIV infection and over 146,000
female adults and adolescents currently live with HIV/AIDS in
the United States, suggesting that the pool of infants at risk for
perinatal HIV infection remains large [1].
Based on the direct relationship between maternal viral load
and risk of vertical transmission, and the potential impact of
directly observed therapy on viral load, we hypothesized that the
provision of directly observed antiretroviral therapy to pregnant
women with HIV infection could result in substantial health and
economic gains, including a diminished need for Caesarean
sections, decreased mother-to-child transmission of HIV, and
increased quality-adjusted life expectancy in infants born to HIV-
infected women. By diverting the large downstream medical costs
associated with pediatric HIV infection, the direct observation of
HAART in the third trimester of pregnancy was projected to be a
highly cost-effective health intervention from a societal perspec-
tive, notwithstanding the short-term costs associated with drug
delivery and directly observed drug administration, and targeting
DOT to women with viral loads .1000 copies/ml on self-
administered HAART was projected to be cost-saving. It is
notable that cost-saving health interventions (such as vaccination
against diseases of childhood) are uncommon in healthcare; most
currently utilized healthcare interventions increase total costs, but
are considered cost-effective if they provide a corresponding
increase in health [50,55]. As the Commission on Macroeconom-
ics and Health of the World Health Organization has suggested
that interventions can be considered cost-effective if they provide
life years at a cost of ,3 times per capita gross national income
(formerly gross domestic product), our analysis suggests that DOT-
CART would be cost-effective not only in high-income countries,
but in a large number of middle-income countries as well [49,56].
While our analysis would strongly support the use of directly
observed HAART in women in the third trimester of pregnancy,
we may have underestimated the potential health benefits of this
intervention. Direct observation of HAART could enhance the
health of infants who acquire HIV infection by reducing the
probability of primary infection with resistant virus [57], and could
also improve future health in the mother by preserving the potency
of antiretroviral classes for future use [6]. DOT might be given to
those women with particularly unsettled social situations who
would be most unlikely to benefit from self-administered HAART,
such as those who are homeless, have substance abuse issues, or
mental illness. Furthermore, the establishment of structured
contact between pregnant, HIV-infected women and public health
personnel, as would occur in the context of directly observed
antiretroviral therapy, has been associated with improved
pregnancy outcomes [58]. Such contacts could link infected
women to improved healthcare after delivery as well as introduce
them to more healthful behaviours while pregnant and perhaps
more open to behaviour change.
Table 3. Projected Average Cost and Effectiveness of Directly Observed HAART in 5000 Simulated Randomized Trials.
Strategy
Average
Cost
% Requiring
Caesarean
Section
% Mother-to-
Child HIV
Transmission
Infant’s Quality-
Adjusted Life
Expectancy
Incremental Cost-
Effectiveness Ratio
($/QALY)
Average Baseline Viral Load ,1000 copies/ml
Self-administered HAART $70,462 67.8 0.44 29.75 ——
HAART with Directly Observed Therapy $72,213 66.5 0.13 29.76 $175,100
Average Baseline Viral Load 1000–10,000 copies/ml
Self-administered HAART $80,852 79.6 3.65 29.65 ——
HAART with Directly Observed Therapy $75,967 70.7 1.25 29.74 Cost-saving*
Average Baseline Viral Load Greater Than 10,000 copies/ml
Self-administered HAART $86,636 83.8 5.62 29.54 ——
HAART with Directly Observed Therapy $85,324 81.1 4.32 29.59 Cost-saving*
NOTE: HAART, highly-active antiretroviral therapy; QALY, quality-adjusted life years.
* A health care intervention is considered to be ‘‘cost-saving’’ when it costs less, but provides more health than, a competing intervention; ‘‘highly cost-effective’’ when
it costs less than the GDP per capita; and ‘‘cost-effective’’ when it is between one and three times a country’s GDP per capita. A cost-saving intervention is always
preferred [49,50].
doi:10.1371/journal.pone.0010154.t003
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PLoS ONE | www.plosone.org 7 April 2010 | Volume 5 | Issue 4 | e10154Table 4. Selected Univariate Sensitivity Analyses of Directly Observed HAART Relative to Self-Administered HAART.
Variable
Discounted Quality Adjusted
Life Expectancy (QALY), Self-
Administered HAART
Discounted Quality Adjusted
Life Expectancy (QALY),
Directly Observed HAART
Cost-Effectiveness of Directly
Observed HAART ($/QALY)
Baseline values 29.72 29.75 Highly cost-effective ($15,430)
Efficacy of self-administered HAART
All women experience 2.0 log10 reduction 29.76 29.76 Dominated {
No sustained reduction with self-administered
HAART *
29.69 29.74 Cost-saving
Reduction in viral load with directly observed
HAART
0.5 Log10 29.76 29.77 Cost-effective ($136,600)
2.4 Log10 29.72 29.76 Cost-saving
Probability of elective Caesarean section
0.5 29.71 29.74 Highly cost-effective ($13,640)
0.7 29.72 29.75 Highly cost-effective ($15,270)
Probability of non-elective Caesarean section
0.09 29.71 29.74 Highly cost-effective ($21,433)
0.21 29.70 29.73 Highly cost-effective ($7,033)
Probability of prematurity
0.06 30.58 30.61 Highly cost-effective ($18,000)
0.27 29.29 29.32 Highly cost-effective ($15,100)
Probability of vertical transmission of HIV {
Lowest 29.70 29.73 Highly cost-effective ($3,833)
Highest 29.74 29.76 Cost-effective ($66,850)
RR of drug toxicity with HAART
Severe toxicity (Baseline probability 0.5%)
2 29.70 29.71 Cost-effective ($46,400)
5 29.71 29.68 Dominated {
Moderate toxicity (Baseline probability 5%)
2 29.58 29.46 Dominated {
5 29.57 29.00 Dominated {
Discounted quality-adjusted life expectancy 1 (HIV Infection/No HIV Infection)
25/31 29.68 29.72 Highly cost-effective ($11,850)
30/31 29.76 29.77 Cost-effective ($59,100)
25/32 30.64 30.69 Highly cost-effective ($11,060)
30/32 30.71 30.73 Highly cost-effective ($18,900)
Antiretroviral costs, including DOT "
Lowest 29.72 29.74 Highly cost-effective ($25,000)
Highest 29.71 29.74 Not cost-effective ($630,360)
Obstetrical costs I
Lowest 29.72 29.75 Highly cost-effective ($20,833)
Highest 29.72 29.75 Highly cost-effective ($11,666)
Lifetime healthcare costs, pediatric HIV infection 1
$140,600 29.72 29.75 Cost-effective ($77,200)
$660,930 29.72 29.75 Cost-saving
Lifetime costs, prematurity 1
$214,200 29.73 29.76 Highly cost-effective ($11,300)
$407,400 29.71 29.74 Highly cost-effective ($16,333)
Discount rate
0 74.64 74.79 Highly cost-effective ($3,360)
7 14.40 14.40 Dominated {
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projections associated with directly observed HAART in preg-
nancy remained robust even in the face of extreme variation in
cost and effectiveness of directly observed therapy. We were able
to identify only one scenario in which direct observation of
HAART in pregnancy would not be preferred to self-administered
Figure 4. Two-Way Sensitivity Analysis on Effectiveness and Cost of Directly Observed Therapy. Each diagonal curve represents a
different estimate of effectiveness (log10 reduction in viral load) of directly observed therapy: 20.5 log10 (thick line, squared); 20.8 log10 (thin solid
line, diamonds); or 21.5 log10 (dashed line, triangles). Incremental cost-effectiveness of directly observed therapy relative to self-administered
antiretrovirals appears on the Y-axis. At each level of effectiveness, increasing the cost of directly observed therapy increases the cost-effectiveness
ratio associated with this intervention; however, only under the most unfavorable cost and effectiveness assumptions does this ratio exceed $50,000
per quality-adjusted life-year (QALY) gained, a commonly cited cost-effectiveness threshold (horizontal dashed line). Values falling below the X-axis
indicate that directly observed therapy is cost-saving.
doi:10.1371/journal.pone.0010154.g004
Variable
Discounted Quality Adjusted
Life Expectancy (QALY), Self-
Administered HAART
Discounted Quality Adjusted
Life Expectancy (QALY),
Directly Observed HAART
Cost-Effectiveness of Directly
Observed HAART ($/QALY)
10 10.57 10.57 Dominated {
NOTE: HAART, highly-active antiretroviral therapy; QALY, quality-adjusted life years. Each estimate based on 10 simulated randomized trials with 1000 women per trial.
* Simulated through 0.75 log10 reduction in viral load in 65% of women, with 0.25 log10 response in the remainder.
{ Highest probability of vertical transmission incorporated upper-bound transmission probability for each maternal viral load, and lower-bound estimate for
effectiveness of Caesarean section, while lowest probability incorporated lower-bound transmission probabilities and upper-bound estimate for effectiveness of
Caesarean section.
{ A health care intervention is ‘‘dominated’’ if it costs more, but provides less health benefit, than a competing intervention. A dominated health intervention is never
preferred [50]. A health care intervention is considered to be ‘‘cost-saving’’ when it costs less a competing intervention; ‘‘highly cost-effective’’ when it costs less than
the GDP per capita; and ‘‘cost-effective’’ when it is between one and three times a country’s GDP per capita, given that the intervention provides more health benefit
than a competing intervention [49,50].
1 Discounted to present value at 3% per annum.
" Incorporated upper- and lower-bound estimates for costs of highly-active antiretroviral therapy (HAART), peripartum zidovudine therapy, and delivery of directly
observed HAART.
I Incorporated upper- and lower-bound estimates for costs of vaginal delivery and Caesarean section.
doi:10.1371/journal.pone.0010154.t004
Table 4. Cont.
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responded maximally to self-administered HAART, one that is
inconsistent with empiric data on the high-risk women who are the
focus of this analysis [14].
Like any mathematical model, the model we present here is a
simplified representation of complicated systems, and is thus
subject to limitations. In particular, a relatively simple model is
limited in its ability to capture the all the complexities related to
the clinical management of HIV in pregnancy; thus, models such
as this one are not a substitute for randomized clinical trials.
However, by synthesizing the best available data on antiretroviral
use in pregnancy and the potential benefits of directly observed
antiretroviral therapy, modeling can help to inform clinical
practice while such trials are pending. Also, by demonstrating
the large potential benefits of a novel approach to therapy, such
modeling may help to mobilize interest in, and support for, such
trials. Our model is particularly important given that this topic is
so difficult to study prospectively, due to the small number of HIV-
infected infants born in the U.S. Multi-centre clinical trials are an
important tool for better defining maximally effective and cost-
effective interventions for prevention of vertical HIV transmission,
especially with mothers at risk of medication non-adherence.
In summary, based on best available data, we projected that
pregnancy provides a unique indication for the use of directly
observed antiretroviral therapy for HIV infection. In this context,
a modest investment of resources would result in substantial health
benefit with a net reduction in societal costs as a result of decreased
mother-to-child HIV transmission. Randomized controlled trials
of directly observed therapy can be advocated as a reasonable next
step in optimizing the prepartum care of HIV-infected women.
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